Slide 1: PANOVA-3: Phase 3 study of TTFields with GnP for LA-PAC
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3: Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for locally advanced pancreatic adenocarcinoma (LA-PAC) Vincent Picozzi, Ha
Slide 2: Key Takeaway Points/Conclusions
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Key Takeaway Points/Conclusions 2 Survival benefit for patients is supported by significantly improved QoL and pain-free survival* compared with GnP alone The only frequently re
Slide 3: LA-PAC, a high unmet need
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. LA- PAC, a high unmet need 3 • Pancreatic adenocarcinoma remains a high unmet need with a modest 5-year survival rate of 8%1,2 ➢About 30–35% of patients present with LA-PAC* and
Slide 4: TTFields therapy
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. TTFields therapy 4 • TTFields are electric fields that disrupt processes critical for cancer cell division1-3 and may trigger an enhanced antitumor immune response • TTFields th
Slide 5: PANOVA-3 study design
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3 study design 5 R 1:1 Gemcitabine 1000 mg/m2† Nab-paclitaxel 125 mg/m2† TTFields therapy* Gemcitabine 1000 mg/m2† Nab-paclitaxel 125 mg/m2† Follow-up Q4W (CT scan Q8W) F
Slide 6: PANOVA-3: Endpoints and statistical analyses
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3: Endpoints and statistical analyses 6 *Compared using one-sided t-test after the directionality of the effect was established; †Compared using one-sided Fisher’s exact
Slide 7: Patient disposition
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Patient disposition 7 † One full GnP cycle is defined as 3 complete administrations per cycle. GnP, gemcitabine/nab-paclitaxel; ITT, intent-to-treat population; mITT, modified i
Slide 8: PANOVA-3: Patients characteristics
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3: Patients characteristics 8 CA19-9, carbohydrate antigen 19-9; ECOG PS, Eastern Cooperation Oncology Group performance status; GnP, gemcitabine/nab-paclitaxel; TTFields
Slide 9: PANOVA-3: Treatment characteristics
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. PANOVA-3: Treatment characteristics 9 GnP, gemcitabine/nab-paclitaxel; NA, not applicable; TTFields, Tumor Treating Fields. • Duration of exposure to gemcitabine and nab-paclita
Slide 10: Primary endpoint: overall survival
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Primary endpoint: overall survival ITT TTFields + GnP GnP P-value Median OS (95% CI) Events 16.2 (15.0, 18.0) 201 14.2 (12.8, 15.4) 230 0.039 HR = 0.82 (95% CI: 0.68, 0.99) 1-ye
Slide 11: Secondary endpoints: PFS and local PFS
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Secondary endpoints: PFS and local PFS 11 PFS – ITT population Local PFS* – ITT population *Progressive disease per revised RECIST version 1.1 in the absence of distant metastas
Slide 12: Post-hoc analysis: Distant PFS
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Post-hoc analysis: Distant PFS* 12 *Defined as progressive disease per revised RECIST version 1.1 in the absence of local progression. CI, confidence interval; GnP, gemcitabine/
Slide 13: Secondary endpoint: pain-free survival
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Secondary endpoint: pain-free survival* 13 CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; TTFields, Tumor Treating
Slide 14: Quality of life: time to deterioration
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. 14 *Defined as the first time-point a patient experienced a deterioration of ≥10 points in the respective QoL scale or death. GnP, gemcitabine/nab-paclitaxel; QoL, quality of li
Slide 15: Safety summary
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Safety summary 15 AE, adverse event; GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor Treating Fields. 1. Von Hoff DD, et al. NEJM 2013;369(18):1691-703. • Rates of AEs were sim
Slide 16: Device-related adverse events
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. 16 Device-related AEs, n (%) TTFields + GnP (N=274) All grades Grade ≥3 Any AE 222 (81.0) 26 (9.5) Any serious AE 1 (0.4) 0 Any AE leading to TTFields discontinuation 23 (8.4) 7
Slide 17: Key Takeaway Points/Conclusions
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Key Takeaway Points/Conclusions 17 Survival benefit for patients is supported by significantly improved QoL and pain-free survival* compared with GnP alone The only frequently r
Slide 18: TTFields With Gemcitabine and Nab-Paclitaxel for LA-PAC publication
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open- Label, Pivotal Phase III PANOVA-3 Study ascopubs.org
Slide 19: Acknowledgements
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. 19 Special thank you to all participating patients, their families, and clinical research teams for your commitment and contributions. Acknowledgements Medical writing support f
Slide 20: Appendix
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. 20 Appendix Dr Vincent Picozzi
Slide 21: Array Layouts
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Array Layouts 21 A) Epigastric-centered with the superior discs row at the level of the xiphoid B) Left hypochondriac-shifted to the left with the superior discs row at the leve
Slide 22: Array Layouts – continued
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Array Layouts – continued 22 E) Left lumbar-shifted to the left with the superior discs row at the inferior the 10th costal cartilage F) Right lumbar-shifted to the right with t
Slide 23: Secondary Endpoints in the mITT population
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Secondary Endpoints in the mITT population 23 mITT TTFields + GnP GnP P-value Median PFS (95% CI) Events 11.2 (9.4, 13.1) 136 10.7 (9.1, 11.5) 121 0.183 HR = 0.84 (95% CI: 0.66,
Slide 24: Overall response rate (ITT population)
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Overall response rate (ITT population) 24 TTFields + GnP (n=244) GnP (n=243) Best overall response, n (%) CR 3 (1.2) 0 PR 85 (34.8) 73 (30.0) SD 142 (58.2) 150 (61.7) PD ORR, %
Slide 25: Salvage Therapies
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Salvage Therapies 25 Summary of Salvage Systemic Therapies TTFields + GnP (N=285) GnP (N=286) Number of Subjects Having Salvage Systemic Therapies 146 (51.2) 134 (46.9) Fluorou
Slide 26: Limitations
PRESENTED BY: © 2025 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. MED-GL-PANC-2500004_V2. Limitations 26 • Investigator's assesment of CT scans for response determination • While protocol included a clear definition of resectability at baseline, there was no such gui